2025年中国创新药行业不断迎来突破，数据显示，今年上半年，我国批准创新药43个，同比增长59%，改革政策红利正在转化为产业发展动力。在这波产业浪潮中，恒瑞医药、百济神州等头部企业凭借差异化布局与硬核实力，构建起中国创新药的全球竞争新优势，推动行业从 “规模仿制” 向 “价值创新” 跃迁。恒瑞医药以年超 60 亿元的研发投入靠前列，2025 年上半年创新药销售额达 95.61 亿元，同比增长 ...
Source Link2025年中国创新药行业不断迎来突破，数据显示，今年上半年，我国批准创新药43个，同比增长59%，改革政策红利正在转化为产业发展动力。在这波产业浪潮中，恒瑞医药、百济神州等头部企业凭借差异化布局与硬核实力，构建起中国创新药的全球竞争新优势，推动行业从 “规模仿制” 向 “价值创新” 跃迁。恒瑞医药以年超 60 亿元的研发投入靠前列，2025 年上半年创新药销售额达 95.61 亿元，同比增长 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.